Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors have transformed cancer therapy, particularly for chronic myeloid leukemia (CML).
• Off-target toxicities and acquired resistance remain significant challenges with existing tyrosine kinase inhibitors.
• The Abelson (ABL) family of tyrosine kinases is a critical target in various malignancies.

Purpose of the Study:

• To review the preclinical and clinical efficacy of novel allosteric inhibitors targeting the Abelson (ABL) family of tyrosine kinases.
• To highlight the potential of these inhibitors in overcoming resistance and reducing toxicities associated with conventional therapies.
• To discuss the application of these inhibitors in primary hematologic and solid malignancies, metastasis, and combination therapies.

Main Methods:

• Review of current literature on preclinical testing of GNF-2 and GNF-5.
• Review of preclinical and clinical testing data for ABL-001.
• Analysis of ongoing clinical trials investigating ABL-001 for CML and solid tumors.

Main Results:

• Allosteric inhibitors like GNF-2, GNF-5, and ABL-001 demonstrate potential efficacy against primary hematologic and solid malignancies.
• These novel agents show promise in combating cancer metastasis.
• Ongoing clinical trials are evaluating ABL-001 for CML and recurrent solid tumors, suggesting therapeutic potential.

Conclusions:

• Novel allosteric inhibitors of the Abelson (ABL) family of tyrosine kinases represent a promising therapeutic strategy.
• These inhibitors offer a potential solution to overcome resistance and toxicity issues in cancer treatment.
• Future research will focus on their role as first-line and salvage therapies for various cancers, including challenging cases where imatinib has failed.